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Osteopontin and Disease Activity in Patients with
Recent-onset Systemic Lupus Erythematosus: 
Results from the SLICC Inception Cohort
Lina Wirestam, Helena Enocsson, Thomas Skogh, Leonid Padyukov, Andreas Jönsen, 
Murray B. Urowitz, Dafna D. Gladman, Juanita Romero-Diaz, Sang-Cheol Bae, Paul R. Fortin,
Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Caroline Gordon, John G. Hanly,
Daniel Wallace, David A. Isenberg, Anisur Rahman, Joan Merrill, Ellen Ginzler, 
Graciela S. Alarcón, W. Winn Chatham, Michelle Petri, Munther Khamashta, Cynthia Aranow,
Meggan Mackay, Mary Anne Dooley, Susan Manzi, Rosalind Ramsey-Goldman, Ola Nived,
Kristjan Steinsson, Asad Zoma, Guillermo Ruiz-Irastorza, Sam Lim, Ken Kalunian, 
Murat Inanc, Ronald van Vollenhoven, Manuel Ramos-Casals, Diane L. Kamen, 
Søren Jacobsen, Christine Peschken, Anca Askanase, Thomas Stoll, Ian N. Bruce, 
Jonas Wetterö, and Christopher Sjöwall
ABSTRACT. Objective. In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect,
and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus
(SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum
OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes.
Methods. We included 344 patients from the Systemic Lupus International Collaborating Clinics
(SLICC) Inception Cohort who had 5 years of followup data available. All patients fulfilled the 1997
American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and
sex-matched population-based controls were analyzed for OPN using ELISA. Disease activity and
damage were assessed at each annual followup visit using the SLE Disease Activity Index 2000
(SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively. 
Results. Compared to controls, baseline OPN was raised 4-fold in SLE cases (p < 0.0001). After
relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict
global damage accrual defined as SDI ≥ 1 at 5 years. However, baseline OPN correlated with
SLEDAI-2K at enrollment into the cohort (r = 0.27, p < 0.0001), and patients with high disease
activity (SLEDAI-2K ≥ 5) had raised serum OPN (p < 0.0001). In addition, higher OPN levels were
found in patients with persistent disease activity (p = 0.0006), in cases with renal involvement 
(p < 0.0001) and impaired estimated glomerular filtration rate (p = 0.01). 
Conclusion. The performance of OPN to predict development of organ damage was not impressive.
However, OPN associated significantly with lupus nephritis and with raised disease activity at
enrollment, as well as over time. (First Release January 15 2019; J Rheumatol 2019;46:492–500;
doi:10.3899/jrheum.180713)
Key Indexing Terms: 
SYSTEMIC LUPUS ERYTHEMATOSUS                  BIOMARKERS                    OSTEOPONTIN
DISEASE ACTIVITY                           ORGAN DAMAGE                                         PROGNOSIS
From the Rheumatology/Division of Neuro and Inflammation Sciences,
Department of Clinical and Experimental Medicine, Linköping University,
Linköping; Department of Medicine, Unit of Rheumatology, Karolinska
Institutet and Karolinska University Hospital, Stockholm; Department of
Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund;
Unit for Clinical Therapy Research (ClinTRID), Karolinska University,
Stockholm, Sweden; Centre for Prognosis Studies in the Rheumatic
Diseases, Toronto Western Hospital and University of Toronto, Toronto,
Ontario; Division of Rheumatology, Centre Hospitalier Universitaire
(CHU) de Québec - Université Laval, Quebec City, Quebec; Division of
Rheumatology, Cumming School of Medicine – University of Calgary,
Calgary, Alberta; Division of Rheumatology, Department of Medicine,
McGill University Health Centre, Montreal, Quebec; Division of
Rheumatology, Department of Medicine and Department of Pathology,
Queen Elizabeth II Health Sciences Centre and Dalhousie University,
Halifax, Nova Scotia; Department of Medicine and Community Health
Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; Instituto
Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico;
Department of Rheumatology, Hanyang University Hospital for Rheumatic
Diseases, Seoul, Korea; Rheumatology Research Group, School of
Immunity and Infection, College of Medical and Dental Sciences,
University of Birmingham, Birmingham; Centre for Rheumatology
Research, University College, London; Lupus Research Unit, The Rayne
Institute, St. Thomas’ Hospital, King’s College London School of
Medicine, London; Lanarkshire Centre for Rheumatology, Hairmyres
Hospital, East Kilbride, Scotland; Arthritis Research UK Centre for
 Rheumatology
The Journal of on June 12, 2019 - Published by www.jrheum.orgDownloaded from 
Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology,
Medicine and Health, The University of Manchester and UK National
Institute for Health Research (NIHR) Manchester Biomedical Research
Centre, Manchester University Foundation Trust, Manchester, UK;
Cedars-Sinai/David Geffen School of Medicine at University of California
at Los Angeles, Los Angeles, California; Department of Clinical
Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City,
Oklahoma; Department of Medicine, State University of New York (SUNY)
Downstate Medical Center, Brooklyn, New York; Department of Medicine,
Division of Clinical Immunology and Rheumatology, University of
Alabama at Birmingham, Birmingham, Alabama; Department of
Rheumatology, Johns Hopkins University School of Medicine, Baltimore,
Maryland; Feinstein Institute for Medical Research, Manhasset, New
York; Division of Rheumatology and Immunology, Department of
Medicine, University of North Carolina, Chapel Hill, North Carolina;
Autoimmunity Institute, Allegheny Health Network, Pittsburgh,
Pennsylvania; Northwestern University and Feinberg School of Medicine,
Chicago, Illinois; Division of Rheumatology, Emory University School of
Medicine, Atlanta, Georgia; University of California San Diego School of
Medicine, La Jolla, California; Division of Rheumatology, Medical
University of South Carolina, Charleston, South Carolina; Division of
Rheumatology, Columbia University Medical Center, New York, New York,
USA; Department of Rheumatology, Center for Rheumatology Research
Fossvogur Landspitali University Hospital, Reyjkavik, Iceland;
Autoimmune Disease Unit, Department of Internal Medicine, Hospital
Universitario Cruces, BioCruces Health Research Institute, University of
the Basque Country, Barakaldo; Josep Font Autoimmune Diseases
Laboratory, Institut d’Investigacions Biomèdiques August Pi i Sunyer
(IDIBAPS), Department of Autoimmune Diseases, Hospital Clínic,
Barcelona, Spain; Division of Rheumatology, Department of Internal
Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey;
Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and
Spine Diseases, Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark; Department of Rheumatology, Kantousspital,
Schaffhausen, Switzerland. 
This work was supported by grants from the Swedish Rheumatism
Association, the County Council of Östergötland, the Swedish Society of
Medicine, the King Gustaf V and Queen Victoria’s Freemasons foundation,
and the King Gustaf V’s 80-year anniversary foundation. Dr. Fortin holds
a Canada Research Chair on Systemic Autoimmune Rheumatic Diseases.
Dr. Bae’s work was supported in part by an unrestricted grant (Hanyang
University 201600000001387). Dr. Gordon’s work was supported by
Lupus UK and the NIHR/Wellcome Trust Clinical Research Facility. The
Hopkins Lupus Cohort is supported by the US National Institutes of
Health (NIH; grant AR43727). The Montreal General Hospital Lupus
Clinic is partially supported by the Singer Family Fund for Lupus
Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic
Diseases at the University of Calgary. Dr. Bruce is supported by Arthritis
Research UK, the NIHR Manchester Biomedical Research Centre and the
NIHR/Wellcome Trust Clinical Research Facility at Manchester University
National Health Service (NHS) Foundation Trust. The views expressed in
this publication are those of the author(s) and not necessarily those of the
NHS, the NIHR, or the Department of Health. Dr. Jacobsen is supported
by the Danish Rheumatism Association (A1028). Dr. Dooley’s work was
supported by NIH grant RR00046.
L. Wirestam, PhD, Rheumatology/Division of Neuro and Inflammation
Sciences, Department of Clinical and Experimental Medicine, Linköping
University; H. Enocsson, PhD, Rheumatology/Division of Neuro and
Inflammation Sciences, Department of Clinical and Experimental
Medicine, Linköping University; T. Skogh, MD, PhD,
Rheumatology/Division of Neuro and Inflammation Sciences, Department
of Clinical and Experimental Medicine, Linköping University; 
L. Padyukov, MD, PhD, Department of Medicine, Unit of Rheumatology,
Karolinska Institutet and Karolinska University Hospital; A. Jönsen, MD,
PhD, Department of Clinical Sciences Lund, Section of Rheumatology,
Lund University; M.B. Urowitz, MD, FRCPC, Professor of Medicine,
Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western
Hospital and University of Toronto; D.D. Gladman, MD, FRCPC,
Professor of Medicine, Centre for Prognosis Studies in the Rheumatic
Diseases, Toronto Western Hospital and University of Toronto;
J. Romero-Diaz, MD, MSc, Instituto Nacional de Ciencias Médicas y
Nutrición; S.C. Bae, MD, Department of Rheumatology, Hanyang
University Hospital for Rheumatic Diseases; P.R. Fortin, MD, MPH,
FRCPC, Professor of Medicine, Division of Rheumatology, CHU de
Québec - Université Laval; J. Sanchez-Guerrero, MD, MSc, Centre for
Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital
and University of Toronto; A.E. Clarke, MD, MSc, Division of
Rheumatology, Cumming School of Medicine–University of Calgary; 
S. Bernatsky, MD, PhD, FRCPC, Professor of Medicine, Division of
Rheumatology, Department of Medicine, McGill University Health Centre;
C. Gordon, MD, Rheumatology Research Group, School of Immunity and
Infection, College of Medical and Dental Sciences, University of
Birmingham; J.G. Hanly, MD, Division of Rheumatology, Department of
Medicine and Department of Pathology, Queen Elizabeth II Health
Sciences Centre and Dalhousie University; D. Wallace, MD, 
Cedars-Sinai/David Geffen School of Medicine, University of California
Los Angeles; D.A. Isenberg, MD, Centre for Rheumatology Research,
University College London; A. Rahman, MD, PhD, Centre for
Rheumatology Research, University College London; J. Merrill, MD,
Department of Clinical Pharmacology, Oklahoma Medical Research
Foundation; E. Ginzler, MD, PhD, Department of Medicine, SUNY
Downstate Medical Center; G.S. Alarcón, MD, MPH, Department of
Medicine, Division of Clinical Immunology and Rheumatology, University
of Alabama at Birmingham; W.W. Chatham, MD, Department of Medicine,
Division of Clinical Immunology and Rheumatology, University of
Alabama at Birmingham; M. Petri, MD, Department of Rheumatology,
Johns Hopkins University School of Medicine; M. Khamashta, MD, Lupus
Research Unit, The Rayne Institute, St. Thomas’ Hospital, King’s College
London School of Medicine; C. Aranow, MD, Feinstein Institute for
Medical Research; M. Mackay, MD, Feinstein Institute for Medical
Research; M.A. Dooley, MD, MPH, Division of Rheumatology and
Immunology, Department of Medicine, University of North Carolina; 
S. Manzi, MD, MPH, Autoimmunity Institute, Allegheny Health Network;
R. Ramsey-Goldman, MD, DrPH, Northwestern University and Feinberg
School of Medicine; O. Nived, MD, PhD, Department of Clinical Sciences
Lund, Section of Rheumatology, Lund University; K. Steinsson, MD,
Department of Rheumatology, Center for Rheumatology Research
Fossvogur Landspitali University Hospital; A. Zoma, MD, Lanarkshire
Centre for Rheumatology, Hairmyres Hospital; G. Ruiz-Irastorza, MD,
Autoimmune Disease Unit, Department of Internal Medicine, Hospital
Universitario Cruces, BioCruces Health Research Institute, University of
the Basque Country; S. Lim, MD, MPH, Division of Rheumatology, Emory
University School of Medicine; K. Kalunian, MD, University of California
San Diego School of Medicine; M. Inanc, MD, Division of Rheumatology,
Department of Internal Medicine, Istanbul Medical Faculty, Istanbul
University; R. van Vollenhoven, MD, ClinTRID, Karolinska University; 
M. Ramos-Casals, MD, Josep Font Autoimmune Diseases Laboratory,
IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic; 
D.L. Kamen, MD, Division of Rheumatology, Medical University of South
Carolina; S. Jacobsen, MD, DMSc, Copenhagen Lupus and Vasculitis
Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet,
Copenhagen University Hospital; C. Peschken, MD, FRCPC, Associate
Professor of Medicine, Department of Medicine and Community Health
Sciences, University of Manitoba; A. Askanase, MD, MPH, Division of
Rheumatology, Columbia University Medical Center; T. Stoll, MD,
Department of Rheumatology, Kantousspital; I.N. Bruce, MD, Arthritis
Research UK Centre for Epidemiology, Centre for Musculoskeletal
Research, Faculty of Biology, Medicine and Health, The University of
Manchester and NIHR Manchester Biomedical Research Centre,
Manchester University Foundation Trust; J. Wetterö, PhD,
Rheumatology/Division of Neuro and Inflammation Sciences, Department
of Clinical and Experimental Medicine, Linköping University; C. Sjöwall,
MD, PhD, Rheumatology/Division of Neuro and Inflammation Sciences,
Department of Clinical and Experimental Medicine, Linköping University.
Address correspondence to Dr. L. Wirestam, AIR/Rheumatology,
Department of Clinical and Experimental Medicine, Campus US,
Linköping University, SE-581 85 Linköping, Sweden. E-mail:
lina.wirestam@gmail.com
Full Release Article. For details see Reprints and Permissions at
jrheum.org
Accepted for publication October 4, 2018.
493Wirestam, et al: Osteopontin in recent-onset SLE
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2019. All rights reserved.
 Rheumatology
The Journal of on June 12, 2019 - Published by www.jrheum.orgDownloaded from 
Systemic lupus erythematosus (SLE) is a multisystemic
inflammatory rheumatic disease that often shows periods of
flares followed by remission. Distinguishing ongoing inflam-
mation attributed to SLE from established organ damage
caused by the disease, medication, or comorbidities remains
a challenge for the clinician. The spectrum of phenotypes
complicates the search for biomarkers that adequately reflect
active disease and/or increasing organ damage. 
    Osteopontin (OPN), an extracellular matrix protein with
multiple functions, has been reported to be involved in
inflammation1. Local production and elevated circulating
levels of OPN have been observed in several autoimmune
diseases, such as multiple sclerosis2, rheumatoid arthritis3,
and SLE4,5. Overexpression of OPN in lupus-prone mice
induces B-cell activation and subsequent production of
anti-dsDNA antibodies6,7, a hallmark of SLE. Intracellular
OPN has been implicated in numerous cellular processes and
its expression is required for Toll-like receptor 9 (TLR-9)–
dependent production of interferon α (IFN-α)8, a central
cytokine in the SLE pathogenesis9. 
    Elevated OPN levels have been found to distinguish SLE
from healthy individuals4,5,10. Further, associations between
OPN and SLE disease activity11 as well as with organ
damage accrual12 have been reported. In addition, elevated
OPN levels have been suggested to precede the development
of organ damage in a study including predominantly pediatric
SLE cases13. We have previously investigated serum OPN in
a cross-sectional Swedish SLE cohort in which OPN
appeared to reflect current global organ damage4. OPN was
also found to associate with lupus nephritis, antiphospholipid
syndrome (APS), and individual clinical and laboratory
criteria of APS. In addition, OPN levels showed significant
correlations with SLE disease activity, particularly in newly
diagnosed cases. 
    The aims of our study were to determine whether OPN (1)
predicts future organ damage, (2) reflects current and/or
persistent disease activity, and (3) associates with certain
disease phenotypes, using a longitudinal international
inception cohort of recent-onset SLE.
MATERIALS AND METHODS
Systemic Lupus International Collaborating Clinics (SLICC) Inception
Cohort. The SLICC Inception Cohort was recruited from 31 centers in 11
countries in North America, Europe, and Asia from 2000 to 2011, as previ-
ously described14,15. Briefly, all clinical data were submitted to the coordi-
nating center at the University of Toronto and patients were reviewed
annually. Laboratory tests necessary to evaluate disease activity, including
complement proteins and autoantibodies, and variables related to organ
damage were performed at the recruiting centers,  Exceptions for this were
OPN and estimated glomerular filtration rate (eGFR) based on serum
creatinine. 
Patients and controls. SLE cases were enrolled within 15 months (mean 6
mos, range 0–15) of SLE diagnosis, which was based on the fulfillment of
at least 4 of the American College of Rheumatology (ACR) 1997 criteria16.
We selected patients from the inception cohort who had baseline serum
available and for which there were 5 years of annual followup data
completed. In addition, absence of organ damage at baseline was a
requirement. At each visit, these measures were assessed: Systemic Lupus
Erythematosus Disease Activity Index 2000 (SLEDAI-2K)17, clinical
SLEDAI (scores for complement consumption and increased DNA binding
subtracted from SLEDAI-2K), serological activity (scores for complement
consumption and increased DNA binding only), and SLICC/ACR damage
index (SDI)18. Patients with “persistent disease activity” were defined as
having SLEDAI-2K scores of ≥ 5 at ≥ 3 separate occasions during the 
5-year followup. At baseline, peripheral venous blood was drawn from each
individual. Sera were prepared and stored at –70°C until analyzed. 
      Sera from population-based controls matched 1:1 according to sex and
age included in the Swedish Epidemiological Investigation of Rheumatoid
Arthritis (EIRA) cohort served as controls for the OPN analyses19. 
      This study was approved by the SLICC data coordinating center’s insti-
tutional research ethics board at the University Health Network (file no.
00-0279). Each of the 33 participating centers’ institutional research ethics
boards approved the SLICC inception cohort study.
OPN immunoassay. A serum- and plasma-validated ELISA kit (Quantikine,
R&D Systems) was used to analyze OPN levels in SLE and control sera. All
OPN assays were performed in Linköping (Sweden), and the analyses were
in accordance with the manufacturers’ instructions. Briefly, serum (diluted
1:25) was added to microwells pre-coated with monoclonal antibodies
directed against human OPN. After incubation and washing, a horse-
radish-peroxide conjugated polyclonal anti-OPN antibody was added and
the plate incubated, followed by the washing and addition of tetramethyl-
benzidine substrate. The enzymatic reaction was stopped by adding 2 N
sulfuric acid and read at 450 nm (plate reader: Sunrise, Tecan; software:
Magellan version 7.1, Tecan). 
Creatinine and eGFR. Serum creatinine was determined using an enzymatic
colorimetric method at the clinical chemistry laboratory (Linköping
University Hospital, Sweden). The 4-variable Modification of Diet in Renal
Disease Study equation was used to calculate eGFR20.
Statistics. Sample size calculation (for comparing 2 groups) revealed that
sera from 208 individuals were needed to detect a significant difference in
OPN levels between SLE patients with versus without any organ damage at
followup. This calculation was based on the following: (1) a power of 80%;
(2) an SD of 36.8 ng/ml, which was the OPN level (SD) in patients with
permanent organ damage using data from our pilot study4; and (3) the
approximation that at least 25% of the patients with SLE would develop any
kind of organ damage during the 5-year followup.
      Independent samples t tests were used to evaluate differences in OPN
levels between SLE patients and controls, and between patients meeting and
not meeting specific ACR criteria.
      Pearson correlation analyses were performed between OPN and disease
activity measures (erythrocyte sedimentation rate, SLEDAI-2K, clinical
SLEDAI, and serological activity) as well as between OPN and the total
number of fulfilled ACR criteria. Significant associations were further
analyzed in a univariate general linear model (GLM) with adjustment for
age, sex, race/ethnicity, and daily glucocorticoid (GC) dose at baseline. In
addition, the association between OPN and nephritis was adjusted for eGFR. 
      ANOVA was used to evaluate differences in OPN levels between patients
with “no damage,” “moderate damage,” and “extensive damage.”
      Binary logistic regression was used to predict damage accrual (global
SDI, as well as organ domains of SDI) with adjustments for baseline data
on age, sex, race/ethnicity, SLEDAI-2K, and GC therapy. Binary logistic
regression was used to predict persistent disease activity with adjustments
for baseline data on age, sex, race/ethnicity, and GC therapy.
      Statistical significance was set at p < 0.05, along with 95% CI. Statistical
analyses were performed with SPSS Statistics 22 (IBM) or GraphPad Prism,
version 5.04 (GraphPad Software).
RESULTS
The study included 344 SLE cases (315 women and 29 men;
mean age 34.0 yrs, range 12–73). The majority of patients 
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(n = 200, 58%) were of white ethnicity. Of the 344 controls
(315 women and 29 men; mean age 34.4 yrs, range 15–73
yrs), 327 (95%) were of white race/ethnicity. Detailed charac-
teristics of the study populations are found in Table 1.
Baseline OPN levels are increased in SLE. Circulating levels
of OPN were markedly higher in patients with SLE (mean
45.4 ng/ml, 95% CI 41.4–49.4) than in the controls (mean
11.8 ng/ml, 95% CI 10.4–13.3, p < 0.0001; Figure 1A). OPN
levels correlated inversely with age, both among the patients
(r = –0.17, p = 0.002) and the controls (r = –0.27, p < 0.0001).
No differences were observed between men and women
among the controls regarding OPN levels. However, among
patients with SLE, men displayed higher OPN levels (mean
79.5 ng/ml, 95% CI 47.0–111.9) compared to women (mean
42.3 ng/ml, 95% CI 39.1–45.4, p < 0.0001). There were no
significant differences in baseline disease activity
(SLEDAI-2K) between men (mean 4.3, 95% CI 2.77–5.9)
and women (mean 5.0, 95% CI 4.5–5.6, p = 0.45). However,
clear differences in OPN levels were identified between
patients of white race/ethnicity (mean 38.2 ng/ml, 95% CI
34.7–41.7) compared to non-whites (mean 55.4 ng/ml, 95%
CI 47.4–63.5, p < 0.0001). Such a difference was not found
among the controls (whites: mean 11.8 ng/ml, 95% CI
10.3–13.3; non-whites: mean 12.3 ng/ml, 95% CI 5.5–19.1;
p = 0.87). Patients of non-white race/ethnicity had higher
disease activity (mean 6.1, 95% CI 5.2–7.0) compared to
whites (mean 4.1, 95% CI 3.5–4.7, p = 0.0002). 
OPN failed to predict damage accrual in adjusted analyses.
At the 3-year followup visit, 63 patients (18%) with SLE had
developed any damage (i.e., SDI ≥ 1), and 98 (29%) showed
damage after 5 years. Because only 18% had an SDI score of
≥ 1 three years post-inclusion, we focused mainly on the
5-year data. A weak correlation was found between baseline
OPN and damage accrual after 5 years (r = 0.15, p = 0.006).
However, in a binary logistic regression analysis with adjust-
ments, OPN levels failed to predict future global damage
when defined as SDI ≥ 1 with a receiver-operating charac-
teristic area under curve (AUC) of 0.67 (p = 0.061; Table 2).
Examining each domain of SDI separately rendered no statis-
tically significant association with OPN levels. However, age
and SLEDAI-2K at baseline significantly predicted organ
damage development at 5 years (Table 2).
    We did not identify any significant differences in baseline
OPN levels when separating patients’ SDI after 5 years into
“no damage” (i.e., SDI = 0, n = 246, mean 41.9 ng/ml, 95%
CI 38.6–45.3), “moderate damage” (SDI 1–2, n = 84, mean
52.5, 95% CI 40.0–65.1), and “extensive damage” (SDI ≥ 3,
n = 14, mean 63.4 ng/ml, 95% CI 38.6–88.2).
OPN reflects disease activity and renal involvement. Baseline
OPN correlated with SLEDAI-2K (r = 0.27, p < 0.0001),
clinical SLEDAI (r = 0.22, p < 0.0001), and serological
activity (r = 0.24, p < 0.0001) at enrollment into the cohort.
Using a binary variable for anti-dsDNA (positive/negative)
showed that patients positive for anti-dsDNA had signifi-
cantly higher OPN levels (mean 55.7 ng/ml, 95% CI
48.2–63.2, n = 150) compared to those that were negative
(mean 37.4 ng/ml, 95% CI 33.6–41.2, n = 194), p < 0.0001.
Patients with low complement (C3 and/or C4) had higher
levels of OPN (mean 54.7 ng/ml, 95% CI 46.6–62.8, n = 130)
compared to those with normal complement (mean 39.7
ng/ml, 95% CI 35.7–43.8, n = 214; p = 0.0003). Patients with
a SLEDAI-2K score of ≥ 5 had higher levels of OPN (mean
56.6 ng/ml, 95% CI 48.3–64.9) than patients with
SLEDAI-2K < 5 (mean 38.5 ng/ml, 95% CI 34.7–42.2; p <
0.0001; Figure 1B). The erythrocyte sedimentation rate corre-
lated with OPN (r = 0.38, p < 0.0001). The above-mentioned
associations remained significant after adjustments for age,
sex, race/ethnicity, and GC therapy in a univariate GLM
analysis.
    We further evaluated associations with different disease
phenotypes (i.e., fulfilled ACR criteria). Only the renal
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Table 1. Baseline characteristics of the 344 SLE patients and 344 popula-
tion-based controls. 
Characteristics                                          Patients with SLE        Controls
Background variables                                                                           
Age, yrs                                                     34.0 (12–73)         34.4 (15–73)
Weight, kg                                             67.5 (32.6–133.0)            NA
Height, cm                                           164.6 (145.0–194.5)          NA
Female sex                                                  315 (91.6)             315 (91.6)
Ethnicities                                                                                         
White                                                       200 (58.1)             327 (95.1)
African descendants                                 52 (15.1)                 4 (1.1)
Asian                                                        64 (18.6)                 3 (0.9)
Other                                                          28 (8.1)                 10 (2.9)
Disease variables                                                                                  
SLEDAI-2K score                                       5.0 (0–30)                  NA
C-reactive protein, mg/l*                                     4.6 (0–114)                    
Erythrocyte sedimentation rate, mm/h#       23.9 (1–99)                    
Glucocorticoid dose at baseline, mg/day     14 (0–90)                      
Creatinine, mg/dl                                      0.7 (0.1–8.1)                   
eGFR, ml/min/1.73 m2                                  119.9 (6.3–473.2)               
Low complement                                        130 (37.8)                     
Increased DNA binding                              150 (43.6)                     
1997 ACR criteria (at enrollment)                                                     NA
1. Malar rash                                               111 (32.3)                     
2. Discoid rash                                             39 (11.3)                      
3. Photosensitivity                                       131 (38.1)                     
4. Oral ulcers                                               125 (36.3)                     
5. Arthritis                                                   249 (72.4)                     
6. Serositis                                                    92 (26.7)                      
7. Renal disorder                                          75 (21.8)                      
8. Neurologic disorder                                  12 (3.5)                       
9. Hematologic disorder                              214 (62.2)                     
10. Immunologic disorder                           265 (77.0)                     
11. Antinuclear antibody                             336 (97.7)                     
Data are presented as mean (range) or n (%). * Performed locally at each
SLICC centre (n = 312). # Performed locally at each SLICC centre (n = 167).
ACR: American College of Rheumatology; SLE: systemic lupus erythe-
matosus; SLEDAI-2K: SLE Disease Activity Index 2000; eGFR: estimated
glomerular filtration rate; SLICC: Systemic Lupus International
Collaborating Clinics; NA: not applicable.
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disorder criterion (ACR-7) reached statistical significance
with higher levels of OPN (mean 63.7 ng/ml, 95% CI
49.9–77.5, n = 75) compared to those without renal
involvement (mean 40.3 ng/ml, 95% CI 37.1–43.5, n = 269;
p < 0.0001; Figure 2A). The association with nephritis
remained significant after adjustments for age, sex,
race/ethnicity, GC therapy, and eGFR in a univariate GLM
analysis. Eighty-three patients had an impaired eGFR (≤ 90
ml/min/1.73 m2), but only 12 patients had an eGFR < 60.
Higher levels of OPN were found in patients with an
impaired eGFR (mean 54.6 ng/ml, 95% CI 42.3–66.9, 
n = 83) compared to those with eGFR > 90 (mean 42.5, 95%
496 The Journal of Rheumatology 2019; 46:5; doi:10.3899/jrheum.180713
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Figure 1. Serum osteopontin (OPN) levels. A. Baseline levels of OPN were signifi-
cantly higher among patients with SLE (mean 45.4 ng/ml, n = 344) compared to
controls (mean 11.8 ng/ml, n = 344). B. Patients with raised disease activity
(SLEDAI-2K ≥ 5) had higher baseline levels of OPN (mean 56.6 ng/ml, n = 131) than
patients with low/no disease activity (SLEDAI-2K < 5; mean 38.5 ng/ml, n = 213).
SLE: systemic lupus erythematosus; SLEDAI-2K: SLE Disease Activity Index 2000. 
Table 2. Binary logistic regression for the outcome of organ damage
(SLICC/ACR Damage Index ≥ 1; yes/no) at 5 years.
Variables                                                            OR (95% CI)               p
OPN at baseline                                              1.01 (1.00–1.02)         0.061
Age at baseline                                               1.03 (1.01–1.05)         0.006
Female sex                                                      0.50 (0.22–1.18)         0.115
White ethnicity                                                0.87 (0.72–1.04)         0.127
Daily glucocorticoid dose at baseline             0.99 (0.97–1.01)         0.241
SLEDAI-2K at baseline                                  1.07 (1.02–1.13)         0.013
SLICC/ACR: Systemic Lupus International Collaborating Clinics/American
College of Rheumatology; OPN: osteopontin; SLEDAI-2K: Systemic Lupus
Erythematosus Disease Activity Index 2000. 
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CI 38.9–46.0, n = 261; p = 0.01; Figure 2B). Of the 75
patients meeting the renal ACR criterion, patients with an
impaired eGFR had higher OPN levels (mean 96.8 ± 24.5
ng/ml, n = 18) compared to those with normal eGFR (mean
53.3 ± 4.2, n = 57; p = 0.006). A weak correlation between
OPN levels and the total number of fulfilled ACR criteria 
(r = 0.17, p = 0.001) was identified. 
OPN predicts persistent disease activity. To further examine
the association between OPN and disease activity, we
separated patients based on persistent disease activity
(defined as SLEDAI-2K scores of ≥ 5 at ≥ 3 separate
occasions during the 5-yr followup). Higher levels of OPN
were found among the 51 patients (15%) with persistent
disease activity (mean 62.0 ng/ml, 95% CI 43.8–80.5)
compared to those without (mean 42.5 ng/ml, 95% CI
39.08–45.9; p = 0.0006; Figure 3A). To evaluate the possible
effect of organ damage on OPN levels in cases with persistent
disease activity (n = 51), those patients who had developed
any damage (i.e., SDI ≥ 1) after 5 years (n = 18) were
compared to those without any damage (n = 33). No statisti-
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Figure 2. Serum osteopontin (OPN) levels in SLE cases with or without renal involvement.
A. Patients meeting the renal disorder criterion (ACR-7) had significantly higher baseline
levels of OPN (mean 63.7 ng/ml, n = 75) compared to those without renal involvement (mean
40.3 ng/ml, n = 269). B. Higher OPN levels were found in patients with impaired eGFR (mean
54.6, n = 83) compared to those with normal eGFR (mean 42.5, n = 261). SLE: systemic lupus
erythematosus; ACR: American College of Rheumatology; eGFR: estimated glomerular
filtration rate. 
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cally significant difference in OPN levels was observed
(Figure 3B). 
    Using a binary logistic regression model with adjustments,
OPN levels were associated with persistent disease activity
(p = 0.011, AUC = 0.66; Table 3). Further adjustment for
damage (SDI) at 5 years did not change this association 
(p = 0.012, AUC = 0.66).
DISCUSSION
In SLE, OPN has been proposed as a useful biomarker of
disease activity4,11, as well as of organ damage4,12,13. Most
previous studies had a cross-sectional design, but in our
present study we aimed to dissect whether baseline OPN
levels could be predictive of future organ damage in a longi-
tudinal cohort. Our results confirm some of the previous
498 The Journal of Rheumatology 2019; 46:5; doi:10.3899/jrheum.180713
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Figure 3. Baseline osteopontin (OPN) levels in patients with persistent disease activity. A.
Higher levels of OPN were found in the 51 patients with persistent disease activity (mean
62.0 ng/ml) compared to those without (mean 42.5 ng/ml, n = 293). B. To investigate the
possible effect of damage on OPN levels in cases with persistent disease activity, we
compared patients who had developed any damage (i.e., SDI ≥ 1) after 5 years to those
without any damage. No significant difference in OPN levels was observed between patients
with any damage (mean 81.5 ng/ml, n = 18) compared with those without (mean 51.4 ng/ml,
n = 33). SDI: Systemic Lupus International Collaborating Clinics/American College of
Rheumatology Damage Index; SLEDAI: Systemic Lupus Erythematosus Disease Activity
Index.
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reports indicating that OPN is associated with disease activity
and lupus nephritis, rather than being a marker of future
damage progression.
    In line with previous findings by our group and
others4,5,10, OPN levels were elevated in patients with SLE
compared with population-based healthy controls. According
to Rullo, et al, increased circulating OPN levels have been
reported to precede increased “cumulative” disease activity
and organ damage in patients with SLE, especially in
pediatric SLE13. In a cross-sectional pilot study, we evaluated
OPN in a cohort of Swedish patients with SLE and found that
circulating OPN levels were associated with global organ
damage4. In our present study, OPN levels at entry into the
SLICC cohort were not significantly associated with damage
accrual after 5 years, using SDI ≥ 1 as cutoff. However, a
larger group of patients with more extensive damage accrual
observed during a longer time period is required to further
resolve this issue. 
    Because OPN showed an inverse correlation with age, and
because differences were observed between men and women
as well as between whites and non-whites, these factors were
adjusted for in the statistical analyses. Rullo, et al13 reported
that high circulating OPN levels preceded increased
“cumulative” SLE disease activity and organ damage over
12 months. In contrast to their study, the SLICC Inception
Cohort consists mainly of adult SLE cases, and there may
also be differences between the studies regarding race or
ethnicities that could have affected the divergent conclusions
of OPN levels as a potential biomarker of future organ
damage.
    In line with earlier reports, we observed an association
between OPN and disease activity, using the SLEDAI-2K4,5.
In our previous pilot study, we noted a robust correlation
between SLEDAI-2K and OPN (r = 0.67, p = 0.028) when
we restricted the analysis to patients with recent-onset
disease4. In our present study, patients with active disease
(i.e., SLEDAI-2K ≥ 5) had higher OPN levels compared to
those with no/low disease activity (i.e., SLEDAI-2K < 5),
and higher OPN levels were also found in patients with
persistent disease activity.
    We further investigated associations of baseline OPN with
different clinical manifestations. Patients meeting the lupus
nephritis criterion displayed higher levels of OPN, which
corroborates the finding in our pilot study4. Patients with
impaired renal function had higher OPN levels, but we did
not find an association between OPN and the renal domain
of SDI. However, such an association has previously been
reported4,11,12, and lupus-prone mice with nephritis have been
shown to express OPN associated with macrophage infil-
tration21. Further, anti-OPN therapy in nephritic rats reduces
albuminuria and invasion of macrophages22, and OPN
knockout mice have less recruitment of macrophages as well
as reduced renal fibrosis23. 
    The reason for elevated OPN in SLE remains unclear, but
it could be of relevance to the SLE pathogenesis that the
intracellular expression of OPN in plasmacytoid dendritic
cells (pDC) is required for TLR-9–dependent production of
IFN-α8. In addition, mutations in tartrate-resistant acid
phosphatase (TRAP) cause spondyloenchondrodysplasia, an
unusual recessive disease associated with short stature, brain
calcifications, and SLE-like autoimmunity24. OPN is a
substrate for TRAP, and TRAP has been shown to co-localize
and physically interact with OPN in pDC and macrophages25.
Lack of TRAP leads to hyperphosphorylation of OPN and
enhanced TLR-9 signaling in pDC with subsequent IFN-α
production, which can cause the SLE-like autoimmunity seen
in patients with spondyloenchondrodysplasia. Thus, future
studies focusing on potential associations between IFN-α and
OPN in SLE are highly warranted. 
    Our study has several strengths, especially the extremely
well-characterized SLE population and the prospective study
design using a large international inception cohort of SLE
patients with 5 years of followup data. Some limitations
should also be mentioned. Although all cases were incident
and enrolled up to 15 months from diagnosis (mean time 6
months), it cannot be excluded that the baseline sample may
have been taken at a timepoint when the patient already
received immunosuppressive therapy or antimalarials. Even
though the control subjects were matched according to sex
and age, the great majority (95%) were white, which did not
reflect the race/ethnicity distribution of the SLE cases (58%
white). Thus, it cannot be excluded that this difference, as
well as the potential effect of environmental factors, may
have influenced the disparity of OPN levels between patients
and controls. The relatively small number of damage events
over 5 years probably reflects well-controlled patients but
generates uncertainties in predicting damage accrual. Finally,
OPN was analyzed at baseline only and we acknowledge that
the predictive value of OPN for different outcome measures
(such as SLE flares or damage accrual) may vary over time
in established disease.
    In early SLE, OPN is elevated and appears to be
associated with renal involvement and higher disease activity
at sampling, as well as over time. We found no distinct
association with accumulation of organ damage. Based on
this, we suggest that raised OPN at SLE onset identify cases
with risk of high and persistent disease activity but may not
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Table 3. Binary logistic regression for the outcome of persistent disease
activity (yes/no) at 5 years.
Variables                                                        OR (95% CI)                p
OPN at baseline                                           1.01 (1.00–1.02)          0.011
Age at baseline                                           0.97 (0.95–1.00)          0.063
Female sex                                                  1.96 (0.51–7.43)          0.325
White ethnicity                                            1.02 (0.82–1.28)          0.854
Daily glucocorticoid dose at baseline         1.00 (0.98–1.02)          0.821
OPN: osteopontin. 
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necessarily lead to accrual of damage within 5 years of
followup.  
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